Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
Association Between Tumor Necrosis Factor-x and Disease Progression in Patients with Multiple Sclerosis
NEJM 325:467-472, Shareif,M.K.&Hentges,R., 1991
Patterns of Disease Activity in Multiple Sclerosis:Clinical and Magnetic Resonance Imaging Study
BMJ 300:631-634, Thompson,A.J.,et al, 1990
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types
AJNR 31:541-548, 390, Vrenken,H.,et al, 2010
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Diffusely Abnormal White Matter in Chronic Multiple Sclerosis: Imaging and Histopathologic Analysis
Arch Neurol 66:601-609, Seewann,A.,et al, 2009
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
The Prevalence of Sjogren Syndrome in Patients with Primary Progressive Multiple Sclerosis
Neurol 57:1359-1363,1357, de Seze,J.,et al, 2001
Progressive Forms of MS:Classification Streamlined or Consensus Overturned?
Lancet 355:162-163, Weinshenker,B.G., 2000
Diagnostic Criteria for Primary Progressive Multiple Sclerosis: A Position Paper
Ann Neurol 47:831-835, Thompson,A.J.,et al, 2000
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998
The Impact of Inpatient Rehabilitation on Progressive Multiple Sclerosis
Ann Neurol 42:236-244, Freeman,J.A.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
Low-Dose (7. 5mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis
Ann Nuerol 37:30-40, 51995., Goodkin,D.E.,et al, 1995
Comparison of Triple Dose vs Std Dose Gadolinium-DTPA for Detect of MRI Enhanc Lesions in Pts with Primary Progr MS
JNNP 59:540-544, Filippi,M.,et al, 1995
Are Magnetic Resonance Findings Pred of Clinical Outcome in Therapeutic Trials in MS? The Dilemma of Interferon-B
Ann Neurol 36:14-18, McDonald,W.I.,et al, 1994
Cladribine in Treatment of Chronic Progressive Multiple Sclerosis
Lancet 344:3-13, Sipe,J.C.,et al, 1994
Oral Megadose Methylprednisolone Therapy in a Pt with Chronic Progressive MS
Neurol 43:230, Gucuyener,K.,et al, 1993
Intermittent Cyclophosphamide Pulse Therapy in Progressive MS:NE Coop MS Trtm Grp
Neurol 43:910-918, Weiner,H.L.,et al, 1993
The Canadian Coop Trial of Cyclophosphamide and Plasma Exchange in Progr MS
The Canadian Coop MS Study Group, Lancet 337:441-4461991., , 1991
Plasma Exchange in Chronic Progressive Multiple Sclerosis:A Long-Term Study
Neurol 41:409-414, Khatri,B.O.,et al, 1991
A Placebo-Controlled, Double-Blind, Randomized, Two-Center, Pilot Trial of Cop 1 in Chronic Progressive MS
Neurol 41:533-539, Bornstein,M.B.,et al, 1991
Intense Immunosuppression in Chronic Progressive Multiple Sclerosis:The Kaiser Study
JNNP 54:1055-1060, Likosky,W.H.,et al, 1991
Efficacy & Toxicity of Cyclosporine in Chronic Progressive Multiple Sclerosis:A Randomized Clinical Trial
M. S. Study Group, Ann Neurol 27:591-605, 5890., , 1990
Benign Versus Chronic Progressive Multiple Sclerosis:Magnetic Resonance Imaging Features
Ann Neurol 25:74-81, Koopmans,R.A.,et al, 1989
A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Chronic Progressive Multiple Sclerosis:Serial Magnetic Resonance Brain Imaging Over Six Months
Ann Neurol 26:248-256, Koopmans,R.A.,et al, 1989
Correlation of Neuropsychological and MRI Findings in Chronic/Progressive Multiple Sclerosis
Neurol 38:1826-1829, Franklin,G.M.,et al, 1988
Cyclophosphamide"Pulses"in Chronic Progressive Multiple Sclerosis, A Preliminary Clinical Trial
Arch Neurol 44:828-832, Myers,L.W.,et al, 1987
Cyclophosphamide in Chronic Progressive Multiple Sclerosis, Maintenance vs Nonmaintenance Therapy
Arch Neurol 44:823-827, Goodkin,D.E.,et al, 1987